Switching tumor necrosis factor alpha inhibitors in HLA-B27-associated severe heel enthesitis

Arthritis Rheum. 2007 Dec 15;57(8):1572-4. doi: 10.1002/art.23096.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Etanercept
  • Fasciitis, Plantar / drug therapy*
  • Fasciitis, Plantar / etiology
  • Fasciitis, Plantar / immunology*
  • HLA-B27 Antigen / metabolism*
  • Heel / pathology
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Spondylarthritis / complications
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • HLA-B27 Antigen
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Adalimumab
  • Etanercept